← All companies ← ICLR Manual IFS → ← IDYA Pharmaceuticals IMMP →
IFRX, InflaRx N.V.
We are a biopharmaceutical company applying our proprietary technologies to discover, develop and commercialize first-in-class, highly potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR.
Activation of the complement system ultimately results in the generation of C5a and C5b by cleavage from complement factor C5.
The C5a/C5aR1 signaling axis is central to this and therefore a critical component of the innate immune system.
The business
What it sells, where the money comes from, the kind of company it is.
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- Situation
- Unprofitable. No meaningful revenue yet; the record is the cash on hand against the burn.
- What moves the needle
- Operating margin has run around −71182% through the cycle, the operating line deeply negative — so the lever is the path to a margin at all: revenue growth against the cost curve and the cash runway, not the level of a margin that isn't there yet. Inventory runs near 17178% of sales, so how fast it turns back into cash — and the risk of writing it down when demand softens — sits alongside the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Every line is arithmetic on the company's filings, shown in full in the sections below.
The record
Ten years of arithmetic, read across the cycle.
The record, 2023–2025
realized figures from each filing · older years to the left| 2023’23 | 2024’24 | 2025’25 | TTMTTMDec 2025 | |
|---|---|---|---|---|
| Income statement | ||||
| €63K | €166K | €29K | €29K | RevenueRevenue |
| (€45M) | (€46M) | (€46M) | (€45M) | Operating incomeOp. inc. |
| n/m | n/m | n/m | n/m | Operating marginOp. mgn |
| (€43M) | (€46M) | (€46M) | (€46M) | Net incomeNet inc. |
| Cash flow & returns | ||||
| (€38M) | (€49M) | (€35M) | (€35M) | Operating cash flowOp. cash |
| €378K | €387K | €342K | €342K | DepreciationDeprec. |
| €4M | (€3M) | €10M | €10M | Working capital & otherWC & other |
| €81K | €47K | €116K | — | CapexCapex |
| 128.5% | 28.3% | 394.4% | — | Capex / revenueCapex/rev |
| (€38M) | (€49M) | (€35M) | — | Owner earningsOwner earn. |
| n/m | n/m | n/m | — | Owner earnings marginOE mgn |
| (€38M) | (€49M) | (€35M) | — | Free cash flowFCF |
| n/m | n/m | n/m | — | Free cash flow marginFCF mgn |
| €2M | — | — | €2M | Dividends paidDiv. paid |
| -578% | -619% | -636% | -636% | Return on equityROE |
| −609% | — | — | −668% | Retained to equityRetained/eq |
| Balance sheet | ||||
| €52M | €18M | €16M | €55M | Cash & investmentsCash+inv |
| — | €24K | — | €24K | ReceivablesReceiv. |
| €11M | €7M | €5M | €5M | InventoryInvent. |
| €12M | €11M | €5M | €5M | Accounts payablePayables |
| (€607K) | (€4M) | (€361K) | (€337K) | Operating working capitalOper. WC |
| €109M | €72M | €54M | €54M | Current assetsCur. assets |
| €17M | €14M | €13M | €13M | Current liabilitiesCur. liab. |
| 6.5× | 5.1× | 4.1× | 4.1× | Current ratioCurr. ratio |
| €120M | €76M | €55M | €55M | Total assetsAssets |
| -1260.5× | -2228.9× | -1161.7× | -1144.5× | Interest coverageInt. cov. |
| €7M | €7M | €7M | €7M | Shareholders’ equityEquity |
| Per share | ||||
| 54.9M | 58.9M | 67.3M | 67.3M | Shares out (diluted)Shares |
| €0.00 | €0.00 | €0.00 | €0.00 | Revenue / shareRev/sh |
| €-0.78 | €-0.78 | €-0.68 | €-0.68 | EPS (diluted)EPS |
| €-0.69 | €-0.82 | €-0.53 | — | Owner earnings / shareOE/sh |
| €-0.69 | €-0.82 | €-0.53 | — | Free cash flow / shareFCF/sh |
| €0.04 | — | — | €0.03 | Dividends / shareDiv/sh |
| €0.00 | €0.00 | €0.00 | — | Cap. spending / shareCapex/sh |
| €0.13 | €0.13 | €0.11 | €0.11 | Book value / shareBVPS |
The record, charted
FY2016–2025Each measure over its full record; the current point and the worst year marked.
Owner earnings vs. net income
Owner earningsNet incomeThe accountant's number, and the cash an owner can take; the gap is the tell.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business turned a €46M loss into (€35M) of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Reported net income | (€46M) | (€46M) | (€43M) | (€29M) | (€46M) |
| Depreciation & amortizationnon-cash charge added back | +€342K | +€387K | +€378K | +€384K | +€372K |
| Working capital & othertiming of cash in and out, other non-cash items | +€10M | −€3M | +€4M | −€5M | +€5M |
| Cash from operations | (€35M) | (€49M) | (€38M) | (€34M) | (€40M) |
| Capital expenditurecash put back in to keep running and to grow | −€116K | −€47K | −€81K | −€162K | −€38K |
| Owner earnings | (€35M) | (€49M) | (€38M) | (€34M) | (€40M) |
| Owner-earnings marginowner earnings ÷ revenue | -120794% | -29317% | -60064% | — | — |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
Will it survive?
- Can it pay its interest? -1144.5×Does not cover its interestOperating income (€45M) ÷ interest expense €39K
What this means
A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.
- Net cashCash €16M + ST investments €39M − debt €2M
What this means
Cash and short-term investments exceed every dollar of debt by €53M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Long (60+ days)DSO 295 + DIO 253 − DPO 271 days
What this means
Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.
Is it a good business?
- Not meaningful hereInvested capital (€7M) = debt €2M + equity €7M − cashIndustry peers: median -101%
What this means
Invested capital is near zero or negative, usually years of buybacks pulling equity down. ROIC explodes or flips sign and stops meaning anything. Judge this one on Owner Earnings instead.
- Owner-earnings margin -60064%Consumes cash through the cycle3-yr median margin, range -120794%–-29317%; latest (€35M) = operating cash (€35M) − maintenance capex €116KIndustry peers: median -12417%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -120794% of revenue this year, a -60064% median across 3 years.
- Are earnings backed by cash? (€35M)Loss, and burning cashNet income (€46M) · cash from operations (€35M)
What this means
The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.
How is the cash used?
- No surplus to allocate
What this means
The business didn't generate positive Owner Earnings this year, so any distributions came from the balance sheet or borrowing, not from operations.
- Investing or harvesting? 0.34×HarvestingCapex €116K ÷ depreciation €342K
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Graham’s defensive tests · 2 of 4 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size —Revenue ≥ $2B (a dollar floor) · €29K
What this means
Big enough to weather a storm. Graham's floor is a dollar figure — about $2B of revenue as a conservative modern stand-in. This company reports in its home currency and we carry no exchange rate, so we show the figure and leave the size bar for you to apply rather than convert it with a number we don't have.
- Strong liquidity PassCurrent ratio ≥ 2× · 4.13×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt PassDebt ≤ working capital · €2M vs €41M WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Earnings stability MissA profit every year (10-yr record) · 10 loss years
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record MissUninterrupted dividends · 2 of 10 yrs
What this means
An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.
- Earnings growth —Earnings +33% over the record · —
What this means
Earnings were negative early in the record, a growth rate isn't meaningful.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are €-0.62/share (latest year €-0.63), the averaged base the calculator's gate runs on, and book value is €0.10/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Does AI threaten the moat?
Low contestabilityThe moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.
The filing raises AI among its risks, but in other terms (security, regulation, energy or the like), not as a competitor to its product.
AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.
Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.
All figures as filed; the source filing is linked above.
Current Position
as of fiscal year-end, Dec 31, 2025Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments€55M
- Receivables€24K
- Inventory€5M
- Accounts payable€5M
- Other current liabilities€8M
From the company's latest filing.
Peers, Pharmaceuticals
The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.
| Company | Revenue | Gross margin | Op. margin | ROIC | Owner earn. margin |
|---|---|---|---|---|---|
| SGMTSagimet Biosciences Inc. Series A | $2M | — | -2844.5% | -59% | — |
| GERNGeron Corporation | $237K | — | -5666.5% | -30% | -6875% |
| CADLCandel Therapeutics Inc. | $125K | — | -20580.8% | — | -17960% |
| CNTBConnect Biopharma Holdings Limited | $64K | — | -90740.6% | -1262% | -80688% |
| AVTXAvalo Therapeutics Inc. | $59K | 63% | -1241.0% | -97% | -606% |
| ALTAltimmune Inc. | $41K | — | -577.1% | -105% | -189% |
| FBRXForte Biosciences Inc. | $36K | — | -37981.2% | -545% | -34751% |
| IFRXInflaRx N.V. | €29K | — | -71182.1% | -52% | -60064% |
| Group median | — | — | -13123.7% | -97% | -17960% |
The price
What a price has to assume.
What the price implies
reverse-DCFEnter the home-market price, not the US ADR quote. InflaRx N.V. reports in EUR, and every figure here (owner earnings, book value, the share count) is on that EUR, ordinary-share basis. Enter the price on the same basis: the local-exchange quote per ordinary share in EUR. A US ADR price in dollars bundles the ADR-to-ordinary ratio and the exchange rate, so it will not reconcile with these figures and would throw the multiple off.
The owner-earnings base could not be formed from this filing’s tagged data (operating cash flow or capital spending is missing), so the owner-earnings reverse-DCF has no base to grow. We read the price from both ends instead: type a price to see the profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.
Enter a price to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.
Manual order: ← ICLR its page in the Manual IFS →
Industry order: ← IDYA the Pharmaceuticals chapter IMMP →